[Long-term survivors of advanced non-small-cell lung cancer: characterisation and prognostic factors in a retrospective study] (Q54706488)

3 June 2018

title

[Long-term survivors of advanced non-small-cell lung cancer: characterisation and prognostic factors in a retrospective study] (English)

1 reference

3 June 2018

author name string

Dujon C

series ordinal

1

1 reference

3 June 2018

Azarian R

series ordinal

2

1 reference

3 June 2018

Petitpretz P

series ordinal

3

1 reference

3 June 2018

publication date

1 November 2009

1 reference

3 June 2018

Revue des Maladies Respiratoires

published in

1 reference

3 June 2018

volume

26

1 reference

3 June 2018

issue

9

1 reference

3 June 2018

page(s)

952-960

1 reference

3 June 2018

Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A).

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Long-term survivors in stage IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Revisions in the International System for Staging Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Non-small cell lung cancer: a study of long-term survival after vinorelbine monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Impact of comorbidity on lung cancer survival

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Differential prognostic impact of comorbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2809%2973330-3

7 January 2021

10.1016/S0761-8425(09)73330-3

Identifiers

DOI

1 reference

3 June 2018

1 reference

3 June 2018